Contemporary Approaches to Immunotherapy of Solid Tumors

被引:1
|
作者
Kuznetsova, Alla V. [1 ,2 ]
Glukhova, Xenia A. [3 ]
Popova, Olga P. [1 ]
Beletsky, Igor P. [3 ]
Ivanov, Alexey A. [1 ]
机构
[1] Russian Univ Med, Formerly AI Evdokimov Moscow State Univ Med & Dent, Lab Mol & Cellular Pathol, Minist Hlth Russian Federat, Bld 4,Dolgorukovskaya Str, Moscow 1127006, Russia
[2] Russian Acad Sci, Koltzov Inst Dev Biol, 26 Vavilov St, Moscow 119334, Russia
[3] Aalto Univ Campus, Onni Biotechnol Ltd, Metallimiehenkuja 10, Espoo 02150, Finland
关键词
adoptive cell transfer; CAR-T cells; CAR-NK cells; CAR-macrophages; antibody-drug conjugate; immune checkpoint inhibitor; immune cell enhancers; tumor microenvironment; CHIMERIC ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; CAR-T-CELLS; ANTIBODY-DRUG CONJUGATE; PANCREATIC DUCTAL ADENOCARCINOMA; NK CELLS; FUNCTIONAL-CHARACTERISTICS; INFILTRATING LYMPHOCYTES; BISPECIFIC ANTIBODY; CANCER;
D O I
10.3390/cancers16122270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The last decade has seen dramatic changes in cancer treatment. Various methods of the immunotherapy of solid tumors, including treatment with targeted monoclonal antibodies, such as immune checkpoint inhibitors, bi- or trispecific immune cell enhancers, and antibody derivatives (e.g., antibody-drug conjugates), in addition to adoptive cell transfer or cell therapy, are being actively developed. A number of these approaches target tumor cells directly, while several other strategies aim to neutralize immunosuppressive elements in the tumor microenvironment (TME) and transform TME from immunologically "cold" to "hot". Although many of these approaches have received clinical approval, each has inherent limitations that are considered in this review. Additionally, we discuss recent innovations in immunotherapy to improve clinical efficacy in solid tumors and strategies to overcome the limitations of various immunotherapy.Abstract In recent years, the arrival of the immunotherapy industry has introduced the possibility of providing transformative, durable, and potentially curative outcomes for various forms of malignancies. However, further research has shown that there are a number of issues that significantly reduce the effectiveness of immunotherapy, especially in solid tumors. First of all, these problems are related to the protective mechanisms of the tumor and its microenvironment. Currently, major efforts are focused on overcoming protective mechanisms by using different adoptive cell therapy variants and modifications of genetically engineered constructs. In addition, a complex workforce is required to develop and implement these treatments. To overcome these significant challenges, innovative strategies and approaches are necessary to engineer more powerful variations of immunotherapy with improved antitumor activity and decreased toxicity. In this review, we discuss recent innovations in immunotherapy aimed at improving clinical efficacy in solid tumors, as well as strategies to overcome the limitations of various immunotherapies.
引用
下载
收藏
页数:40
相关论文
共 50 条
  • [31] Mast cells as targets for immunotherapy of solid tumors
    Oldford, Sharon A.
    Marshall, Jean S.
    MOLECULAR IMMUNOLOGY, 2015, 63 (01) : 113 - 124
  • [32] Antibody targeted CpG for the immunotherapy of solid tumors
    Jang, Julie K.
    Hu, Peisheng
    Li, Zhongjun
    Khawli, Leslie A.
    Epstein, Alan L.
    CANCER RESEARCH, 2012, 72
  • [33] Challenges of evaluating immunotherapy efficacy in solid tumors
    Rilan Bai
    Wenqian Li
    Nawen Du
    Jiuwei Cui
    Chinese Journal of Cancer Research, 2019, 31 (06) : 853 - 861
  • [34] Unlocking solid tumors to nano-immunotherapy
    Carreira, Barbara
    Acurcio, Rita C.
    Matos, Ana I.
    Moura, Liane M.
    Santos, Ana C.
    Gouveia, Raquel
    Cordeiro, Jessica
    Peres, Carina
    Vaskovich-Koubi, Daniela
    Kleiner, Ron
    Pozzi, Sabina
    Satchi-Fainaro, Ronit
    Florindo, Helena F.
    CANCER RESEARCH, 2024, 84 (06)
  • [35] ACTIVE SPECIFIC IMMUNOTHERAPY OF HUMAN SOLID TUMORS
    ROSATO, FE
    MILLER, E
    ROSATO, EF
    BROWN, A
    WALLACK, MK
    JOHNSON, J
    MOSKOWITZ, A
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 277 (SEP20) : 332 - 338
  • [36] NONSPECIFIC (BCG) IMMUNOTHERAPY OF HUMAN SOLID TUMORS
    LANGLEY, JR
    HOTCHKISS, W
    ROSATO, FE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 : 75 - 76
  • [37] CYTOKINE COMBINATIONS IN IMMUNOTHERAPY FOR SOLID TUMORS - A REVIEW
    HEATON, KM
    GRIMM, EA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 37 (04) : 213 - 219
  • [38] Transcriptomic biomarkers of immunotherapy response in solid tumors
    Gyorffy, Balazs
    Kovacs, Szonja Anna
    Fekete, Janos Tibor
    CANCER RESEARCH, 2023, 83 (07)
  • [39] Immunotherapy for solid tumors-a review for surgeons
    Saied, Abdul
    Pillarisetty, Venu G.
    Katz, Steven C.
    JOURNAL OF SURGICAL RESEARCH, 2014, 187 (02) : 525 - 535
  • [40] Immunotherapy combinations for the treatment of patients with solid tumors
    Virginia Bluthgen, Maria
    Bast, Neus
    Recondo, Gonzalo
    FUTURE ONCOLOGY, 2020, 16 (23) : 1715 - 1736